Aim: In this study, we aimed to evaluate the clinical response, prognosis, and side effects of tocilizumab treatment among moderate, severe, and critical patients hospitalized due to coronavirus disease 2019 pneumonia. Materials and methods: Retrospectively, 48 adult patients were included. Age, gender, co-morbid conditions, chest CT findings, and treatment modalities were recorded, and laboratory findings and the necessity of oxygen on the first, third and seventh day of tocilizumab were evaluated. Results: While receiving tocilizumab, 34 (70.8%) of the patients were hospitalized in the intensive care unit, and 14 (29.1%) were in an inpatient clinic. On the seventh day, mean lymphocyte counts, mean C- reactive levels, and oxygen saturations were improved significantly (p: <0.001). All 14 patients whose tocilizumab treatment was initiated in an inpatient clinic survived, and none of them had needed an intensive care unit admission. The overall mortality rate was 45.8% (22/48). The average day of death was 16.6±12.6 (6 to 53). Among patients whose tocilizumab treatment was started in an intensive care unit, the mortality rate was 64.7% (22/34). Factors that were found to be significantly associated with mortality were as; hospitalization in an intensive care unit while receiving tocilizumab, receiving non-invasive/invasive mechanical ventilation, having bacterial superinfection, and high involvement in CT imaging (> 50%) at presentation. No serious side effects were observed during/after tocilizumab treatment. Conclusions: In patients with moderate disease who have clinical signs of deterioration, starting early tocilizumab treatment may prevent admission to intensive care, reduce the necessity for supplemental oxygen, and improve clinical and laboratory response. Keywords: SARS-CoV-2, tocilizumab, mortality

Koagülaz negatif stafilokok (KNS) grubunun bir üyesi olan Staphylococcus lugdunensis, normal cilt florası olarak insanların %30 ila %50'sinde çoğunlukla kasık bölgesi, koltuk altı ve burun deliklerinde olmak üzere kolonize olur. Patojen olarak ilk tanımlandığı 1988 yılından bu yana, giderek artan sayıda ve geniş bir yelpazede bulaşıcı hastalıkların bir nedeni olarak rapor edilmiştir. Bunlar yumuşak doku, kemik, eklem, idrar yolu enfeksiyonları ve çoğunlukla doğal sol kalp kapakçıklarını tutan, apse oluşumu, hızlı kapak yıkımı, yüksek emboli oranı ve çoğu durumda kapak değiştirme operasyonu gerekliliği ile karakterize agresif bir enfektif endokardit (EE) formu olarak klinikte karşımıza çıkar. Bu çalışmada kronik böbrek yetmezliği öyküsü olan bir erkek hastada hem triküspit hem de pulmoner kalp kapakçıklarını tutan S. lugdunensis'e bağlı şiddetli destrüktif EE olgusu sunulmaktadır. Hastada daptomisin artı klindamisin tedavisinin 42. gününde kapak replasmanı operasyonuna ihtiyaç duyulmuş ve ilk tanısından 58 gün sonra şifa ile taburcu edilmiştir.